ProAxsis specialises in the development and commercialisation of in vitro diagnostic laboratory assays and point–of–care tests designed to measure active protease biomarkers of disease.

8

Employees

2013

Founded

4 Products

CE Mark

ProAxsis has utilised its proprietary ProteaseTag technology to develop and commercialise our first lateral flow device (NEATstik), thereby enabling rapid point–of–care measurement of active neutrophil elastase, a proven biomarker of lung infection and inflammation. 

The exciting potential of NEATstik was recently highlighted in a European Respiratory Journal publication (Shoemark et al, 2019). The company is actively seeking commercialisation partners for the product.

ProAxsis has registered CE Marks for laboratory–based immunoassays, designed to specifically measure the active form of neutrophil elastase and proteinase 3 (as biomarkers in diseases such as COPD, bronchiectasis, cystic fibrosis and alpha–1 anti–trypsin deficiency) and plasmin (as a measure of fibrosis).

The company additionally offers a range of sample analysis and R&D services at its purpose–built laboratory in Northern Ireland, and is currently supporting a number of clinical trial programmes for small and large pharmaceutical companies.

Visit website
  • Life Science, Engineering

    Causeway Sensors Ltd

    Causeway Sensors are revolutionising the discovery and development of biotherapeutics using label–free plasmonic nanostructures

    Read more
  • Environmental, Engineering, Scientific

    MOF Technologies Ltd

    World leaders in the manufacture, testing and commercialisation of Metal Organic Frameworks; a new generation of adsorbents used in cleantech applications across the world.

    Read more
  • Digital, Engineering

    Titan IC Systems Ltd

    Titan IC is an innovative technology company leading the way in delivering accelerated search and analytics within high–speed networks and big data worldwide.

    Read more
  • Life Science

    Re–Vana Therapeutics Ltd

    Re–Vana Therapeutics is an ocular pharmaceuticals and drug delivery company focused on the development and commercialisation of innovative long–acting biodegradable drug delivery platforms to treat chronic eye diseases.

    Read more